Danish drugmaker Novo Nordisk (NYSE: NVO) has been on an epic bull run ever since the Food and Drug Administration (FDA) approved its weight-loss medication, Wegovy, in the summer of 2021. The pharmaceutical giant's shares have more than doubled in value over this period, while the broader markets have struggled due to a confluence of geopolitical headwinds, the lingering impacts of the pandemic, and rising interest rates.

NVO data by YCharts.

Continue reading

Source Fool.com